{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:57:05Z","timestamp":1770753425297,"version":"3.50.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ningbo medical science and technology project","award":["2020Y45"],"award-info":[{"award-number":["2020Y45"]}]},{"name":"medical and health science and technology program of Zhejiang province","award":["2020KY912"],"award-info":[{"award-number":["2020KY912"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is no consensus on the optimal secondary antifungal prophylaxis (SAP) regimen in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). The purpose of this study was to evaluate the efficacy and safety of posaconazole oral suspension as secondary prophylaxis of invasive fungal disease (IFD) for allo-HSCT patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively reviewed clinical data from prior IFD patients who received posaconazole oral suspension as systemic antifungal prophylaxis between June 2016 and January 2021 and have a follow-up period of 1\u00a0year after HSCT. The clinical outcomes of patients with a prior history of IFD (n\u2009=\u200930) and those without (n\u2009=\u200993) were compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The 1-year cumulative incidence of prophylaxis failure was 58.3% in the group with prior history of IFD and 41.6% in the group without a prior history of IFD (p\u2009=\u20090.459). The cumulative incidence of proven, probable or possible IFD within 1\u00a0year after allo-HSCT was 23.1% in the group with prior history of IFD and 14.1% in the group without prior history of IFD (p\u2009=\u20090.230). There was no significant difference between the cumulative incidence of proven or probable IFD within 1-year after allo-HSCT in the group with a prior history of IFD and the group without (p\u2009=\u20090.807). Multivariate logistic regression revealed cytomegalovirus disease as risk factor for post-transplantation IFD occurrence in posaconazole oral suspension prophylaxis. There was not a significant difference in overall survival between the patients with IFD history and those without (P\u2009=\u20090.559).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study support that allo-HSCT recipients with a prior history of IFD and normal GI absorption can choose posaconazole oral suspension as a safe and effective SAP option.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07442-y","type":"journal-article","created":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T06:16:04Z","timestamp":1652595364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study"],"prefix":"10.1186","volume":"22","author":[{"given":"Peipei","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzhi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youqian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,15]]},"reference":[{"issue":"3","key":"7442_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11684-018-0641-0","volume":"13","author":"L Wang","year":"2019","unstructured":"Wang L, Wang Y, Hu J, Sun Y, Huang H, Chen J, et al. Clinical risk score for invasive fungal diseases in patients with hematological malignancies undergoing chemotherapy: China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study. Front Med. 2019;13(3):365\u201377.","journal-title":"Front Med"},{"issue":"1","key":"7442_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-016-0305-y","volume":"9","author":"L Gao","year":"2016","unstructured":"Gao L, Sun Y, Meng F, Han M, Huang H, Wu D, et al. Antifungal prophylaxis of patients undergoing allogenetic hematopoietic stem cell transplantation in China: a multicenter prospective observational study. J Hematol Oncol. 2016;9(1):97.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"7442_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115461","volume":"9","author":"M Liu","year":"2014","unstructured":"Liu M, Li Y, Zhang Y, Zhao X, Zhai B, Zhang Q, et al. Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease: a retrospective analysis. PLoS ONE. 2014;9(12): e115461.","journal-title":"PLoS ONE"},{"issue":"8","key":"7442_CR4","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.bbmt.2014.04.016","volume":"20","author":"Q Liu","year":"2014","unstructured":"Liu Q, Lin R, Sun J, Xiao Y, Nie D, Zhang Y, et al. Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis. Biol Blood Marrow Transplant. 2014;20(8):1198\u2013203.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 4","key":"7442_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1469-0691.2008.01978.x","volume":"14","author":"M Richardson","year":"2008","unstructured":"Richardson M, Lass-Florl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008;14(Suppl 4):5\u201324.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"7442_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Winston DJ. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348\u201359.","journal-title":"N Engl J Med."},{"issue":"4","key":"7442_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","volume":"356","author":"AJ Ullmann","year":"2007","unstructured":"Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335\u201347.","journal-title":"N Engl J Med"},{"issue":"1","key":"7442_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3111\/13696998.2015.1094477","volume":"19","author":"TS Chan","year":"2016","unstructured":"Chan TS, Marcella SW, Gill H, Hwang YY, Kwong YL. Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital. J Med Econ. 2016;19(1):77\u201383.","journal-title":"J Med Econ"},{"issue":"3","key":"7442_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105886","volume":"55","author":"MS Copley","year":"2020","unstructured":"Copley MS, Waldron M, Athans V, Welch SC, Brizendine KD, Cober E, et al. Itraconazole vs posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: a retrospective study. Int J Antimicrob Agents. 2020;55(3): 105886.","journal-title":"Int J Antimicrob Agents."},{"issue":"2","key":"7442_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.mycmed.2017.11.003","volume":"28","author":"L Tang","year":"2018","unstructured":"Tang L, Yang XF, Qiao M, Zhang L, Tang XW, Qiu HY, et al. Posaconazole vs voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: a retrospective study. J Mycol Med. 2018;28(2):379\u201383.","journal-title":"J Mycol Med."},{"issue":"2","key":"7442_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2146\/ajhp110149","volume":"69","author":"AK O'Sullivan","year":"2012","unstructured":"O\u2019Sullivan AK, Weinstein MC, Pandya A, Thompson D, Langston AA, Perfect JR, et al. Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in US patients with graft-versus-host disease. Am J Health Syst Pharm. 2012;69(2):149\u201356.","journal-title":"Am J Health Syst Pharm."},{"issue":"3","key":"7442_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367\u20139.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"23","key":"7442_CR13","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1182\/blood.2019000396","volume":"134","author":"AN Wilkinson","year":"2019","unstructured":"Wilkinson AN, Chang K, Kuns RD, Henden AS, Minnie SA, Ensbey KS, et al. IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling. Blood. 2019;134(23):2092\u2013106.","journal-title":"Blood"},{"issue":"12","key":"7442_CR14","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"7442_CR15","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1086\/514341","volume":"44","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289\u201397.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"7442_CR16","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/phar.1533","volume":"35","author":"AJ Guarascio","year":"2015","unstructured":"Guarascio AJ, Slain D. Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole. Pharmacotherapy. 2015;35(2):208\u201319.","journal-title":"Pharmacotherapy"},{"issue":"24","key":"7442_CR17","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1182\/blood.2020005884","volume":"136","author":"PP-ARCD Kontoyiannis","year":"2020","unstructured":"Kontoyiannis PP-ARCD. How I transplant a patient with a history of invasive fungal disease. Blood. 2020;136(24):2741\u201353.","journal-title":"Blood"},{"issue":"9","key":"7442_CR18","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1182\/blood-2006-03-008706","volume":"108","author":"R Martino","year":"2006","unstructured":"Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2006;108(9):2928\u201336.","journal-title":"Blood"},{"issue":"8","key":"7442_CR19","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1086\/591969","volume":"47","author":"C Garcia-Vidal","year":"2008","unstructured":"Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47(8):1041\u201350.","journal-title":"Clin Infect Dis"},{"key":"7442_CR20","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.3389\/fmicb.2019.02903","volume":"10","author":"SE Kidd","year":"2019","unstructured":"Kidd SE, Chen SC, Meyer W, Halliday CL. A new age in molecular diagnostics for invasive fungal disease: are we ready? Front Microbiol. 2019;10:2903.","journal-title":"Front Microbiol"},{"issue":"10273","key":"7442_CR21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","volume":"397","author":"JA Maertens","year":"2021","unstructured":"Maertens JA, Rahav G, Lee DG, Ponce-de-Leon A, Ramirez Sanchez IC, Klimko N, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021;397(10273):499\u2013509.","journal-title":"Lancet"},{"key":"7442_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3389\/fmicb.2020.00349","volume":"11","author":"W Li","year":"2020","unstructured":"Li W, Xia F, Zhou H, Qiu H, Wu D, Ma X, et al. Efficacy of posaconazole prophylaxis for fungal disease in hematology patients treated with chemotherapy and transplantation: an open-label, prospective, observational study. Front Microbiol. 2020;11:349.","journal-title":"Front Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07442-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07442-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07442-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T06:16:52Z","timestamp":1652595412000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07442-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,15]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7442"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07442-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,15]]},"assertion":[{"value":"10 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local Ethic Committee (The Affiliated People's Hospital of Ningbo University, Ningbo, China) in 2016. This study was conducted in accordance with the Declaration of Helsinki\u00a0Written informed consent was provided by patients or by their legal representatives.\u00a0All methods in this study were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient. All authors gave their consent for publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"465"}}